JW (Cayman) Therapeutics CoJWCTF 30 Days Payable is 102.37 as of Dec. 2025, which is 335% above its 10-year median of 23.51. GuruFocus rates JWCTF with a GF Score™ of 30/100 and a GF Value™ of $0.64 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 705 Biotechnology companies, JW (Cayman) Therapeutics Co ranks worse than 55.46% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JWCTF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JW (Cayman) Therapeutics Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Days Payable distribution charts can be found below:
* The bar in red indicates where JW (Cayman) Therapeutics Co's Days Payable falls into.
JW (Cayman) Therapeutics Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JW (Cayman) Therapeutics Co (JWCTF) has a Days Payable of 102.37 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on JW (Cayman) Therapeutics Co and its competitors. This is 335% above median its historical median of 23.51. Over the past decade, JW (Cayman) Therapeutics Co's Days Payable has ranged from 12.33 to 88.61. According to the industry distribution chart, JW (Cayman) Therapeutics Co ranks #391 out of 705 companies in the Biotechnology industry, placing it in the top 55.5%.
Is JW (Cayman) Therapeutics Co's Days Payable too high?
JW (Cayman) Therapeutics Co's current Days Payable of 102.37 is 335% above median its 10-year median of 23.51. Over the past 10 years, this metric has ranged from a low of 12.33 to a high of 88.61. The Biotechnology industry median Days Payable is 113.36. JW (Cayman) Therapeutics Co's value of 102.37 is 9.7% below this industry median. Based on the distribution chart, JW (Cayman) Therapeutics Co ranks #391 out of 705 companies in the Biotechnology industry, which is below the industry midpoint. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, JW (Cayman) Therapeutics Co ranks #391 out of 705 companies for Days Payable. This places JW (Cayman) Therapeutics Co in the lower half of its industry. The industry median Days Payable is 113.36. JW (Cayman) Therapeutics Co's value of 102.37 is 9.7% below this benchmark. Historically, JW (Cayman) Therapeutics Co's own Days Payable has ranged from 12.33 to 88.61 over the past decade. While the company's 10-year median is 23.51 vs. the industry median of 113.36, JW (Cayman) Therapeutics Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JW (Cayman) Therapeutics Co's current Days Payable of 102.37 is 9.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on JW (Cayman) Therapeutics Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JW (Cayman) Therapeutics Co's current Days Payable is 102.37, which is 335% above median its own 10-year median of 23.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.64, compared to a current price of $0.24 — trading 62.9% below its estimated fair value. The current Days Payable is 102.37, which is 335% above median its 10-year median of 23.51 and 9.7% below the Biotechnology industry median of 113.36. JW (Cayman) Therapeutics Co's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current Days Payable is 102.37 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued.
The current stock price of $0.24 is trading 62.9% below its estimated GF Value™ of $0.64.
GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.
Key valuation signals for JWCTF:
Days Payable: 102.37 (335% above median its 10-year median of 23.51)
GF Value™: $0.64 vs. price of $0.24 (62.9% below fair value)
Industry Position: 9.7% below the Biotechnology median (#391 of 705)
No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
30GF Score
Get the complete analysis for JWCTF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JWCTF has been successfully added to your 
